ArticleJournal of the American Academy of Dermatology2016
Imaging mass spectrometry assists in the classification of diagnostically challenging atypical Spitzoid neoplasms.
Article in Journal of the American Academy of Dermatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 41 citations in OpenAlex.
- Visualizing the molecular landscape of skin: applications and perspectives of mass spectrometry imaging.Analytical and bioanalytical chemistry · 2026Review
- Article
- Article
- Imaging Mass Spectrometry for the Classification of Melanoma Based onInternational journal of molecular sciences · 2023Article
- Diagnosis of melanoma by imaging mass spectrometry: Development and validation of a melanoma prediction model.Journal of cutaneous pathology · 2021Article
- Discovery of Prognostic Markers for Early-Stage High-Grade Serous Ovarian Cancer by Maldi-Imaging.Cancers · 2020Article
- Differentiation of lymphocytic-plasmacytic enteropathy and small cell lymphoma in cats using histology-guided mass spectrometry.Journal of veterinary internal medicine · 2020Article
- The Importance of Clinical Tissue Imaging.Clinical mass spectrometry (Del Mar, Calif.) · 2019Article
- Novel methods in adrenal research: a metabolomics approach.Histochemistry and cell biology · 2019Review
- Site-to-Site Reproducibility and Spatial Resolution in MALDI-MSI of Peptides from Formalin-Fixed Paraffin-Embedded Samples.Proteomics. Clinical applications · 2019Article
- Mass Spectrometry Imaging and Integration with Other Imaging Modalities for Greater Molecular Understanding of Biological Tissues.Molecular imaging and biology · 2018Review
- Next Generation Histology-Directed Imaging Mass Spectrometry Driven by Autofluorescence Microscopy.Analytical chemistry · 2018Article
- Round robin study of formalin-fixed paraffin-embedded tissues in mass spectrometry imaging.Analytical and bioanalytical chemistry · 2018Article
- Genomic Landscape of Spitzoid Neoplasms Impacting Patient Management.Frontiers in medicine · 2018Review
- Mass Spectrometry Imaging Can Distinguish on a Proteomic Level Between Proliferative Nodules Within a Benign Congenital Nevus and Malignant Melanoma.The American Journal of dermatopathology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 18 institutions in 10 countries.
Funding
Abstract
backgroundPreviously, using imaging mass spectrometry (IMS), we discovered proteomic differences between Spitz nevi and Spitzoid melanomas.
objectiveWe sought to determine whether IMS can assist in the classification of diagnostically challenging atypical Spitzoid neoplasms (ASN), to compare and correlate the IMS and histopathological diagnoses with clinical behavior.
methodsWe conducted a retrospective collaborative study involving centers from 11 countries and 11 US institutions analyzing 102 ASNs by IMS. Patients were divided into clinical groups 1 to 4 representing best to worst clinical behavior. The association among IMS findings, histopathological diagnoses, and clinical groups was assessed.
resultsThere was a strong association between a diagnosis of Spitzoid melanoma by IMS and lesions categorized as clinical groups 2, 3, and 4 (recurrence of disease, metastases, or death) compared with clinical group 1 (no recurrence or metastasis beyond a sentinel node) (P < .0001). Older age and greater tumor thickness were strongly associated with poorer outcome (P = .01).
conclusionsIMS diagnosis of ASN better predicted clinical outcome than histopathology. Diagnosis of Spitzoid melanoma by IMS was strongly associated with aggressive clinical behavior. IMS analysis using a proteomic signature may improve the diagnosis and prediction of outcome/risk stratification for patients with ASN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.